Evidence map›Paper›PMID 35604769›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2022

Advances towards Cell-Specific Gene Transfection: A Small-Molecule Approach Allows Order-of-Magnitude Selectivity.

Thies Dirksmeyer, Paul Stahl, Cecilia Vallet, Shirley Knauer, Michael Giese, Carsten Schmuck, Christoph Hirschhäuser

Open access · hybridAbstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Thies DirksmeyerInstitute of Organic Chemistry, University of Duisburg-Essen, 45117, Essen, Germany.
Paul StahlInstitute of Biology, University of Duisburg-Essen, 45117, Essen, Germany.ORCID http://orcid.org/0000-0001-6300-0006
Cecilia ValletInstitute of Biology, University of Duisburg-Essen, 45117, Essen, Germany.ORCID http://orcid.org/0000-0002-9413-846X
Shirley KnauerInstitute of Biology, University of Duisburg-Essen, 45117, Essen, Germany.ORCID http://orcid.org/0000-0003-4321-0924
Michael GieseInstitute of Organic Chemistry, University of Duisburg-Essen, 45117, Essen, Germany.ORCID http://orcid.org/0000-0001-6355-536X
Carsten SchmuckInstitute of Organic Chemistry, University of Duisburg-Essen, 45117, Essen, Germany.ORCID http://orcid.org/0000-0001-6062-0357
Christoph HirschhäuserInstitute of Organic Chemistry, University of Duisburg-Essen, 45117, Essen, Germany.ORCID http://orcid.org/0000-0002-9409-1550
University of Duisburg-Essen · DE

Funding

Deutsche ForschungsgemeinschaftEvonik Stiftung
6 · The paper itself

Abstract

A transfection vector that can home in on tumors is reported. Whereas previous vectors that allow moderately cell selective gene transfection used larger systems, this small-molecule approach paved the way for precise structure-activity relationship optimization. For this, biotin, which mediates cell selectivity, was combined with the potent DNA-binding motif tetralysine-guanidinocarbonypyrrol via a hydrophilic linker, thus enabling SAR-based optimization. The new vector mediated biotin receptor (BR)-selective transfection of cell lines with different BR expression levels. Computer-based analyses of microscopy images revealed a preference of one order of magnitude for the BR-positive cell lines over the BR-negative controls.

Indexed as

Genetic VectorsNeoplasmsBiotinCell LineHumansTransfectionBiotinbiotincancer cell targetingcell-penetrating peptidesgene technologysmall molecules

Identifiers

PMID35604769
PMCPMC9401007
OpenAlexW4281290628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.